Free Trial
NASDAQ:NXTC

NextCure Q2 2026 Earnings Results & Report

NextCure logo
$5.95 -0.32 (-5.12%)
Closing price 03:58 PM Eastern
Extended Trading
$5.76 -0.18 (-3.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextCure missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$2.80 versus the -$1.95 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

NextCure EPS Results

Actual EPS
-$2.80
Consensus EPS
-$1.95
Beat/Miss
Missed by -$0.85
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

NextCure's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules

NextCure Q2 2026 Earnings FAQ

NextCure (NASDAQ:NXTC) reported earnings of -$2.80 per share for Q2 2026, missing the consensus estimate of -$1.95. The report was announced on Thursday, August 6, 2026.

NextCure's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for NextCure on the company's earnings history page.

NextCure Earnings Headlines

NextCure (NXTC) Expected to Post Quarterly Earnings on Monday
NextCure CMO Departs Amid Pending Avere Merger
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
NextCure Faces Court Review of Reverse Stock Split
NextCure Ends Beltsville Lease to Cut Operating Costs
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC) (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations. Michael Richman has served as the company’s chief executive officer and has been involved in its development as a biotechnology business.

View NextCure Profile